Differential roles of androgen receptor in prostate development and cancer progression

Androgen Action in Prostate Cancer

Volumn , Issue , 2009, Pages 73-89

  Yeh, Shuyuan ^a   Niu, Yuanjie ^a   Miyamoto, Hiroshi ^a   Chang, Tamin ^a   Chang, Chawnshang ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881078415     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69179-4_3     Document Type: Chapter

References (104)

1. Aalinkeel, R., Nair, M.P., Sufrin, G., Mahajan, S.D., Chadha, K.C., Chawda, R.P. and Schwartz, S. A. (2004) Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res, 64, 5311-5321.
2. Akakura, K., Bruchovsky, N., Goldenberg, S.L., Rennie, P.S., Buckley, A.R. and Sullivan, L.D. (1993) Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer, 71, 2782-2790.
3. Alvarado, C., Beitel, L.K., Sircar, K., Aprikian, A., Trifiro, M. and Gottlieb, B. (2005) Somatic mosaicism and cancer: a micro-genetic examination into the role of the androgen receptor gene in prostate cancer. Cancer Res, 65, 8514-8518.
4. Attiga, F.A., Fernandez, P.M., Weeraratna, A.T., Manyak, M.J. and Patierno, S.R. (2000) Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res, 60, 4629-4637.
5. Baldassarre, G., Belletti, B., Nicoloso, M.S., Schiappacassi, M., Vecchione, A., Spessotto, P., Morrione, A., Canzonieri, V. and Colombatti, A. (2005) p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell, 7, 51-63.
6. Belletti, B., Nicoloso, M.S., Schiappacassi, M., Chimienti, E., Berton, S., Lovat, F., Colombatti, A. and Baldassarre, G. (2005) p27(kip1) functional regulation in human cancer: a potential target for therapeutic designs. Curr Med Chem, 12, 1589-1605.
7. Bentel, J.M. and Tilley, W.D. (1996) Androgen receptors in prostate cancer. J Endocrinol, 151, 1-11.
8. Bhowmick, N.A. and Moses, H.L. (2005) Tumor-stroma interactions. Curr Opin Genet Dev, 15, 97-101.
9. Bouzin, C. and Feron, O. (2007) Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat, 10, 109-120.
10. Buchanan, G., Greenberg, N.M., Scher, H.I., Harris, J.M., Marshall, V.R. and Tilley, W.D. (2001a) Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res, 7, 1273-1281.
11. Buchanan, G., Irvine, R.A., Coetzee, G.A. and Tilley, W.D. (2001b) Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev, 20, 207-223.
12. Buchanan, G., Yang, M., Harris, J.M., Nahm, H.S., Han, G., Moore, N., Bentel, J.M., Matusik, R. J., Horsfall, D.J., Marshall, V.R., Greenberg, N.M. and Tilley, W.D. (2001c) Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol, 15, 46-56.
13. Chen, G., Wang, X., Zhang, S., Lu, Y., Sun, Y., Zhang, J., Li, Z. and Lu, J. (2005) Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics. Prostate, 63, 395-406.
14. Chodak, G.W., Kranc, D.M., Puy, L.A., Takeda, H., Johnson, K. and Chang, C. (1992) Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol, 147, 798-803.
15. Condon, M.S. (2005) The role of the stromal microenvironment in prostate cancer. Semin Cancer Biol, 15, 132-137.
16. Corey, E., Quinn, J.E., Bladou, F., Brown, L.G., Roudier, M.P., Brown, J.M., Buhler, K.R. and Vessella, R.L. (2002) Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate, 52, 20-33.
17. Crook, J.M., Szumacher, E., Malone, S., Huan, S. and Segal, R. (1999) Intermittent androgen suppression in the management of prostate cancer. Urology, 53, 530-534.
18. Culig, Z. and Bartsch, G. (2006) Androgen axis in prostate cancer. J Cell Biochem, 99, 373-381.
19. Cunha, G.R. and Lung, B. (1978) The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J Exp Zool, 205, 181-193.
20. Cunha, G.R. and Young, P. (1991) Inability of Tfm (testicular feminization) epithelial cells to express androgen-dependent seminal vesicle secretory proteins in chimeric tissue recombi-nants. Endocrinology, 128, 3293-3298.
21. Cunha, G.R., Donjacour, A.A., Cooke, P.S., Mee, S., Bigsby, R.M., Higgins, S.J. and Sugimura, Y. (1987) The endocrinology and developmental biology of the prostate. Endocr Rev, 8, 338-362.
22. Cunha, G.R., Battle, E., Young, P., Brody, J., Donjacour, A., Hayashi, N. and Kinbara, H. (1992) Role of epithelial-mesenchymal interactions in the differentiation and spatial organization of visceral smooth muscle. Epithelial Cell Biol, 1, 76-83.
23. Cunha, G.R., Ricke, W., Thomson, A., Marker, P.C., Risbridger, G., Hayward, S.W., Wang, Y.Z., Donjacour, A.A. and Kurita, T. (2004) Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol, 92, 221-236.
24. Donjacour, A.A. and Cunha, G.R. (1988) The effect of androgen deprivation on branching morphogenesis in the mouse prostate. Dev Biol, 128, 1-14.
25. Donjacour, A.A. and Cunha, G.R. (1993) Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or andro-gen-insensitive mice. Endocrinology, 132, 2342-2350.
26. Duff, J. and McEwan, I.J. (2005) Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol Endocrinol, 19, 2943-2954.
27. Egawa, S., Takashima, R., Matsumoto, K., Mizoguchi, H., Kuwao, S. and Baba, S. (2000) A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. Jpn J Clin Oncol, 30, 21-26.
28. Feltquate, D., Nordquist, L., Eicher, C., Morris, M., Smaletz, O., Slovin, S., Curley, T., Wilton, A., Fleisher, M., Heller, G. and Scher, H.I. (2006) Rapid androgen cycling as treatment for patients with prostate cancer. Clin Cancer Res, 12, 7414-7421.
29. Fenton, M.A., Shuster, T.D., Fertig, A.M., Taplin, M.E., Kolvenbag, G., Bubley, G.J. and Balk, S. P. (1997) Functional characterization of mutant androgen receptors from androgen-indepen-dent prostate cancer. Clin Cancer Res, 3, 1383-1388.
30. Fujimoto, N., Miyamoto, H., Mizokami, A., Harada, S., Nomura, M., Ueta, Y., Sasaguri, T. and Matsumoto, T. (2007) Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Cancer Invest, 25, 32-37.
31. Gingrich, J.R., Barrios, R.J., Kattan, M.W., Nahm, H.S., Finegold, M.J. and Greenberg, N.M. (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res, 57, 4687-4691.
32. Gottlieb, B., Beitel, L.K., Wu, J.H. and Trifiro, M. (2004) The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat, 23, 527-533.
33. Hammacher, A., Thompson, E.W. and Williams, E.D. (2005) Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int J Biochem Cell Biol, 37, 442-450.
34. Han, G., Foster, B.A., Mistry, S., Buchanan, G., Harris, J.M., Tilley, W.D. and Greenberg, N.M. (2001) Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem, 276, 11204-11213.
35. Han, G., Buchanan, G., Ittmann, M., Harris, J.M., Yu, X., Demayo, F.J., Tilley, W. and Greenberg, N.M. (2005) Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA, 102, 1151-1156.
36. Hayward, S.W., Baskin, L.S., Haughney, P.C., Foster, B.A., Cunha, A.R., Dahiya, R., Prins, G.S. and Cunha, G.R. (1996a) Stromal development in the ventral prostate, anterior prostate and seminal vesicle of the rat. Acta Anat, 155, 94-103.
37. Hayward, S.W., Cunha, G.R. and Dahiya, R. (1996b) Normal development and carcinogenesis of the prostate. A unifying hypothesis. Ann N Y Acad Sci, 784, 50-62.
38. Hayward, S.W., Rosen, M.A. and Cunha, G.R. (1997) Stromal-epithelial interactions in the normal and neoplastic prostate. Br J Urol, 79 Suppl 2, 18-26.
39. Hayward, S.W., Haughney, P.C., Rosen, M.A., Greulich, K.M., Weier, H.U., Dahiya, R. and Cunha, G.R. (1998) Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation, 63, 131-140.
40. Heemers, H.V. and Tindall, D.J. (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev, 28, 778-808.
41. Heinlein, C.A. and Chang, C. (2002) Androgen receptor (AR) coregulators: an overview. Endocr Rev, 23, 175-200.
42. Heinlein, C.A. and Chang, C. (2004) Androgen receptor in prostate cancer. Endocr Rev, 25, 276-308.
43. Heitzer, M.D. and DeFranco, D.B. (2006) Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res, 66, 7326-7333.
44. Higano, C.S., Ellis, W., Russell, K. and Lange, P.H. (1996) Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology, 48, 800-804.
45. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H. and Hittmair, A. (1996) Androgen receptor status of lymph node metastases from prostate cancer. Prostate, 28, 129-135.
46. Hofmeister, V., Schrama, D. and Becker, J.C. (2008) Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother, 57, 1-17.
47. Hu, Y.C., Yeh, S., Yeh, S.D., Sampson, E.R., Huang, J., Li, P., Hsu, C.L., Ting, H.J., Lin, H.K., Wang, L., Kim, E., Ni, J. and Chang, C. (2004) Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem, 279, 33438-33446.
48. Huggins, C. and Hodges, C.V. (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin, 22, 232-240.
49. Hurtado-Coll, A., Goldenberg, S.L., Gleave, M.E. and Klotz, L. (2002) Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology, 60, 52-56; discussion 56.
50. Isaacs, J.T. (1984) Antagonistic effect of androgen on prostatic cell death. Prostate, 5, 545-557.
51. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M.J. (2008) Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.
52. Johnson, M.A., Iversen, P., Schwier, P., Corn, A.L., Sandusky, G., Graff, J. and Neubauer, B.L. (2005) Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Prostate, 62, 322-338.
53. Kahl, P., Gullotti, L., Heukamp, L.C., Wolf, S., Friedrichs, N., Vorreuther, R., Solleder, G., Bastian, P.J., Ellinger, J., Metzger, E., Schule, R. and Buettner, R. (2006) Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res, 66, 11341-11347.
54. Kinbara, H. and Cunha, G.R. (1996) Ductal heterogeneity in rat dorsal-lateral prostate. Prostate, 28, 58-64.
55. Kuhn, R., Schwenk, F., Aguet, M. and Rajewsky, K. (1995) Inducible gene targeting in mice. Science, 269, 1427-1429.
56. Kurita, T., Wang, Y.Z., Donjacour, A.A., Zhao, C., Lydon, J.P., O'Malley, B.W., Isaacs, J.T., Dahiya, R. and Cunha, G.R. (2001) Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ, 8, 192-200.
57. Kyprianou, N. and Isaacs, J.T. (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 122, 552-562.
58. Lakso, M., Sauer, B., Mosinger, B., Jr., Lee, E.J., Manning, R.W., Yu, S.H., Mulder, K.L. and Westphal, H. (1992) Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci USA, 89, 6232-6236.
59. Lapouge, G., Erdmann, E., Marcias, G., Jagla, M., Monge, A., Kessler, P., Serra, S., Lang, H., Jacqmin, D., Bergerat, J.P. and Ceraline, J. (2007) Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-a new paradigm for cooperation among prostate tumor cells. Int J Cancer, 121, 1238-1244.
60. Li, W., Cavasotto, C.N., Cardozo, T., Ha, S., Dang, T., Taneja, S.S., Logan, S.K. and Garabedian, M.J. (2005) Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function. Mol Endocrinol, 19, 2273-2282.
61. Linja, M.J. and Visakorpi, T. (2004) Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol, 92, 255-264.
62. Litvinov, I.V., De Marzo, A.M. and Isaacs, J.T. (2003) Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab, 88, 2972-2982.
63. Liu, A.Y., Roudier, M.P. and True, L.D. (2004) Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol, 165, 1543-1556.
64. Marcelli, M., Ittmann, M., Mariani, S., Sutherland, R., Nigam, R., Murthy, L., Zhao, Y., DiCon-cini, D., Puxeddu, E., Esen, A., Eastham, J., Weigel, N.L. and Lamb, D.J. (2000) Androgen receptor mutations in prostate cancer. Cancer Res, 60, 944-949.
65. Michalaki, V., Syrigos, K., Charles, P. and Waxman, J. (2004) Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer, 90, 2312-2316.
66. Mirosevich, J., Bentel, J.M., Zeps, N., Redmond, S.L., D'Antuono, M.F. and Dawkins, H.J. (1999) Androgen receptor expression of proliferating basal and luminal cells in adult murine ventral prostate. J Endocrinol, 162, 341-350.
67. Miyamoto, H., Altuwaijri, S., Cai, Y., Messing, E.M. and Chang, C. (2005) Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog, 44, 1-10.
68. Mohler, J.L., Chen, Y., Hamil, K., Hall, S.H., Cidlowski, J.A., Wilson, E.M., French, F.S. and Sar, M. (1996) Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res, 2, 889-895.
69. Monge, A., Jagla, M., Lapouge, G., Sasorith, S., Cruchant, M., Wurtz, J.M., Jacqmin, D., Bergerat, J.P. and Ceraline, J. (2006) Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer. Cell Mol Life Sci, 63, 487-497.
70. Nagabhushan, M., Miller, C.M., Pretlow, T.P., Giaconia, J.M., Edgehouse, N.L., Schwartz, S., Kung, H.J., de Vere White, R.W., Gumerlock, P.H., Resnick, M.I., Amini, S.B. and Pretlow, T.G. (1996) CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res, 56, 3042-3046.
71. Nagy, A. (2000) Cre recombinase: the universal reagent for genome tailoring. Genesis, 26, 99-109.
72. Nelius, T., Filleur, S., Yemelyanov, A., Budunova, I., Shroff, E., Mirochnik, Y., Aurora, A., Veliceasa, D., Xiao, W., Wang, Z. and Volpert, O.V. (2007) Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer, 121, 999-1008.
73. Nelson, J.B. and Carducci, M.A. (2000) Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer. Cancer Invest, 18, 87-96.
74. Nishimura, K., Ting, H.J., Harada, Y., Tokizane, T., Nonomura, N., Kang, H.Y., Chang, H.C., Yeh, S., Miyamoto, H., Shin, M., Aozasa, K., Okuyama, A. and Chang, C. (2003) Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor cor-egulator. Cancer Res, 63, 4888-4894.
75. Niu, Y., Altuwaijr, S., Lai, K.-P., Wu, C.-T., Ricke, W.A., Messing, E.M., Yao, J., Yeh, S. and Chang, C. (2008a) Androgen receptor is a tumor suppressor and stimulator in prostate cancer metastasis. Proc Natl Acad Sci USA, 105, 12182-12187.
76. Niu, Y., Altuwaijri, S., Yeh, S., Lai, K.-P., Yu, S., Chuang, K.-H., Huang, S.-P., Lardy, H. and Chang, C. (2008b) Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA, 105, 12188-12193.
77. Papandreou, C.N., Usmani, B., Geng, Y., Bogenrieder, T., Freeman, R., Wilk, S., Finstad, C.L., Reuter, V.E., Powell, C.T., Scheinberg, D., Magill, C., Scher, H.I., Albino, A.P. and Nanus, D. M. (1998) Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med, 4, 50-57.
78. Patrawala, L., Calhoun, T., Schneider-Broussard, R., Li, H., Bhatia, B., Tang, S., Reilly, J.G., Chandra, D., Zhou, J., Claypool, K., Coghlan, L. and Tang, D.G. (2006) Highly purified CD44 + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and meta-static progenitor cells. Oncogene, 25, 1696-1708.
79. Pilatus, U., Ackerstaff, E., Artemov, D., Mori, N., Gillies, R.J. and Bhujwalla, Z.M. (2000) Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the metabolic Boyden chamber. Neoplasia, 2, 273-279.
80. Pinkas, J. and Teicher, B.A. (2006) TGF-beta in cancer and as a therapeutic target. Biochem Pharmacol, 72, 523-529.
81. Prins, G.S. and Putz, O. (2008) Molecular signaling pathways that regulate prostate gland development. Differentiation, 76, 641-659.
82. Rahman, M., Miyamoto, H. and Chang, C. (2004) Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res, 10, 2208-2219.
83. Roy, A.K., Lavrovsky, Y., Song, C.S., Chen, S., Jung, M.H., Velu, N.K., Bi, B.Y. and Chatterjee, B. (1999) Regulation of androgen action. Vitam Horm, 55, 309-352.
84. Sadi, M.V., Walsh, P.C. and Barrack, E.R. (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer, 67, 3057-3064.
85. Saleem, M., Kweon, M.H., Johnson, J.J., Adhami, V.M., Elcheva, I., Khan, N., Bin Hafeez, B., Bhat, K.M., Sarfaraz, S., Reagan-Shaw, S., Spiegelman, V.S., Suri, V. and Mukhtar, H. (2006) S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the tran-scriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci USA, 103, 14825-14830.
86. Sharifi, N., Dahut, W.L. and Figg, W.D. (2008) Secondary hormonal therapy for prostate cancer: what lies on the horizon? BJU Int, 101, 271-274.
87. Shi, X.B., Ma, A.H., Xia, L., Kung, H.J. and de Vere White, R.W. (2002) Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res, 62, 1496-1502.
88. Sugimura, Y., Cunha, G.R. and Donjacour, A.A. (1986a) Morphogenesis of ductal networks in the mouse prostate. Biol Reprod, 34, 961-971.
89. Sugimura, Y., Cunha, G.R. and Donjacour, A.A. (1986b) Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biol Reprod, 34, 973-983.
90. Tanimura, Y., Kokuryo, T., Tsunoda, N., Yamazaki, Y., Oda, K., Nimura, Y., Naing Mon, N., Huang, P., Nakanuma, Y., Chen, M.F., Jan, Y.Y., Yeh, T.S., Chiu, C.T., Hsieh, L.L. and Hamaguchi, M. (2005) Tumor necrosis factor alpha promotes invasiveness of cholangiocarci-noma cells via its receptor, TNFR2. Cancer Lett, 219, 205-213.
91. Taplin, M.E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K., Keer, H.N. and Balk, S.P. (1995) Mutation of the androgen-receptor gene in metastatic androgen-inde-pendent prostate cancer. N Engl J Med, 332, 1393-1398.
92. Tilley, W.D., Buchanan, G., Hickey, T.E. and Bentel, J.M. (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res, 2, 277-285.
93. van der Kwast, T.H., Schalken, J., Ruizeveld de Winter, J.A., van Vroonhoven, C.C., Mulder, E., Boersma, W. and Trapman, J. (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer, 48, 189-193.
94. van Leenders, G.J. and Schalken, J.A. (2003) Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol, 46 Suppl, S3-S10.
95. van Leenders, G.J., Aalders, T.W., Hulsbergen-van de Kaa, C.A., Ruiter, D.J. and Schalken, J.A. (2001) Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol, 195, 563-570.
96. Webber, M.M., Trakul, N., Thraves, P.S., Bello-DeOcampo, D., Chu, W.W., Storto, P.D., Huard, T.K., Rhim, J.S. and Williams, D.E. (1999) A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis, 20, 1185-1192.
97. Wu, C.T., Altuwaijri, S., Ricke, W.A., Huang, S.P., Yeh, S., Zhang, C., Niu, Y., Tsai, M.Y. and Chang, C. (2007) Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA, 104, 12679-12684.
98. Wu, X., Wu, J., Huang, J., Powell, W.C., Zhang, J., Matusik, R.J., Sangiorgi, F.O., Maxson, R.E., Sucov, H.M. and Roy-Burman, P. (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev, 101, 61-69.
99. Yang, Z., Chang, Y.J., Miyamoto, H., Ni, J., Niu, Y., Chen, Z., Chen, Y.L., Yao, J.L., di Sant'Agnese, P.A. and Chang, C. (2007a) Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol, 21, 343-358.
100. Yang, Z., Chang, Y.J., Miyamoto, H., Yeh, S., Yao, J.L., di Sant'Agnese, P.A., Tsai, M.Y. and Chang, C. (2007b) Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54. Endocrinology, 148, 1340-1349.
101. Yeh, S., Miyamoto, H. and Chang, C. (1997) Hydroxyflutamide may not always be a pure antiandrogen. Lancet, 349, 852-853.
102. Yeh, S., Miyamoto, H., Shima, H. and Chang, C. (1998) From estrogen to androgen receptor: new pathway for sex hormones in prostate. Proc Natl Acad Sci USA, 95, 5527-5532.
103. Yeh, S., Tsai, M.Y., Xu, Q., Mu, X.M., Lardy, H., Huang, K.E., Lin, H., Yeh, S.D., Altuwaijri, S., Zhou, X., Xing, L., Boyce, B.F., Hung, M.C., Zhang, S., Gan, L. and Chang, C. (2002) Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA, 99, 13498-13503.
104. Yeh, S., Hu, Y.C., Wang, P.H., Xie, C., Xu, Q., Tsai, M.Y., Dong, Z., Wang, R.S., Lee, T.H. and Chang, C. (2003) Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med, 198, 1899-1908.